- FDA has approved a Pfizer nasal spray for treatment of migraines called zavegepant, marketed as Zavzpret.
- In a clinical trial of 1,269 patients, 24% of those taking the medication reported freedom from pain compared to 15% who took a placebo.
- It's the first and only nasal spray for migraines to block the release of proteins called calcitonin gene-related peptides.
- Nasal sprays are absorbed more quickly than pills, with some side effects like altered sense of taste, nasal discomfort and nausea reported.
- It's safe for patients who have had a heart attack or a stroke.
F.D.A. Approves New Nasal Spray for Migraines
The FDA has approved a nasal spray for treatment of migraines that uses a different therapy from other nasal products on the market for severe headache pain. The drug, called zavegepant, performed better than a placebo in relieving pain and patients’ most bothersome symptoms.